We can’t show the full text here under this license. Use the link below to read it at the source.
MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma
MicroRNA-101 may reverse chemotherapy resistance by blocking a key enzyme in brain cancer
AI simplified
Abstract
MicroRNA-101 (miR-101) was significantly downregulated in TMZ-resistant glioblastoma multiforme (GBM) cells and human specimens.
- Over-expression of miR-101 may sensitize resistant GBM cells to temozolomide (TMZ).
- Downregulation of glycogen synthase kinase 3β (GSK3β) is associated with the sensitization of GBM cells to TMZ.
- GSK3β inhibition could enhance the effectiveness of TMZ through repression of the MGMT gene via promoter methylation.
- Decreased expression of miR-101 is related to poor prognosis in GBM patients, indicating its potential as a prognostic marker.
- This suggests that targeting miR-101 could offer a novel strategy for overcoming TMZ resistance in GBM.
AI simplified